Health
Amylyx Drug Shows Promise in Hypoglycemia Study
The drug avexitide, developed by Amylyx, significantly reduced the rate of serious low blood sugar events in a Phase 3 trial for post-bariatric hypoglycemia.
Coverage timeline — 1 article
STAT News
In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…
2026-08-18 11:01 UTC